---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-271112"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:06:54.492937+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q3 net loss improves to $0.41/share; highlights evorpacept benefit in CD47-high gastric cancer

## Summary
- GAAP net loss for Q3 2025 was $22.1M ($0.41/share), improved from $30.7M ($0.58/share) in Q3 2024.
- Cash, cash equivalents and investments at Sept 30, 2025: $66.5M; runway into Q1 2027.
- ASPEN-06 exploratory analysis: In CD47-high retained HER2+ gastric cancer, evorpacept combo achieved 65.0% ORR vs 26.1% for control; median DOR 25.5 vs 8.4 months.
- Phase 1 ALX2004 (EGFR-targeted ADC) cleared first dose cohort; currently enrolling 2 mg/kg dose; initial safety data expected 1H 2026.
- Barbara Klencke, M.D., appointed interim Chief Medical Officer; brings 30+ years oncology drug development experience.

## SEC filing metadata
- accession: 0001193125-25-271112
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312525271112/0001193125-25-271112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312525271112/alxo-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-271112
- JSON: https://secwatch.observer/filing/0001193125-25-271112.json
- Plain text: https://secwatch.observer/filing/0001193125-25-271112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.